| |
Article Title |
Author(s) |
Pages |
|
|
|
Editorial Board
|
|
IFC
|
|
|
|
Preface
19 February 2010
Hepatic fibrosis is a hot topic in basic and clinical hepatology. I had the honor of organizing the APASL single topic conference on hepatic fibrosis (Cairo 2008) and secured the participation of the ...
|
Gamal Shiha
|
S1
|
|
|
|
Using a recombinant single chain antibody for targeting liver myofibroblasts with anti-fibrogenic therapeutics
02 March 2010
Abstract: Chronic liver disease results in a liver scarring response termed fibrosis. Excessive scarring leads to cirrhosis which is associated with high morbidity and mortality. The only treatment fo...
|
Angela Douglass,
Karen Wallace,
Matthew Koruth,
Caroline Barelle,
Andrew J. Porter,
Matthew C. Wright
et al.
|
S3-S6
|
|
|
|
New developments in the treatment of chronic hepatitis B
14 January 2010
Effective treatment of chronic hepatitis B (CHB) is a rapidly evolving subject in medicine. It opened in the early 1990s when recombinant α-interferons, 2a (IFN-α2a) and α2b (IFN-α2b), became availabl...
|
Stephanos J. Hadziyannis
|
S7-S9
|
|
|
|
Hepatic progenitor cells in acute and chronic liver disease: Clinical aspects
19 February 2010
In humans, increasing evidence supports the existence and activation of hepatic progenitor cells (HPCs) in different liver diseases, which are all characterised by a variable degree of hepatocyte loss...
|
Frederik Nevens,
Aezam Katoonizadeh,
Tania Roskams
|
S10-S11
|
|
|
|
Potential novel biomarkers for monitoring the fibrogenic process in liver
18 January 2010
Abstract: The clinical course of chronic liver diseases is significantly dependent on the progression rate of fibrosis, that is, the unstructured replacement of injured parenchyma by extracellular mat...
|
Axel M. Gressner,
Mohamed Rizk,
Chunfang Gao,
Olav A. Gressner
|
S12-S16
|
|
|
|
Pathology of NASH and fibrosis
25 February 2010
Abstract: Non-alcoholic steatohepatitis (NASH) is a progressive liver disease that has gained recognition in the last two decades. It may even account for some of the cases previously diagnosed as cry...
|
Puja Sakhuja
|
S17-S20
|
|
|
|
Antifibrotic agents emerging from traditional herbal medicine
20 January 2010
Hepatic fibrogenesis is a complex and dynamic pathological process that is controlled by the synthesis and degradation of extracellular matrix materials, including fibril-forming collagens. The prolif...
|
Norifumi Kawada
|
S21-S22
|
|
|
|
End-points in hepatitis B treatment
08 March 2010
High prevalence of viral hepatitis B infection is associated with chronic hepatitis and serious liver diseases. The health burden of chronic hepatitis B (CHB) is high in Asia-Pacific region and, to a...
|
Nancy Leung
|
S23-S24
|
|
|
|
Molecular basis and clinical endopoints for the development of antifibrogenic drugs
22 February 2010
The last two decades have witnessed a considerable progress in the understanding of the mechanisms responsible for the fibrogenic progression of chronic liver diseases. However, no drugs have been app...
|
Massimo Pinzani
|
S25-S26
|
|
|
|
Targeting fibrosis with selective drug carriers
22 February 2010
Abstract: This review summarises the progress that has been made in recent years in the field of drug delivery to the hepatic stellate cells (HSCs). HSCs are the crucial cells in the pathogenesis of l...
|
Klaas Poelstra,
Rick Greupink,
Leonie Beljaars
|
S27-S29
|
|
|
|
Steatosis, fibrosis and hepatitis C virus infection
17 February 2010
Hepatic steatosis is a common histological feature in chronic hepatitis C. Its prevalence varies between 40% and 85% (mean 55%), depending on the characteristics of the population studied in terms of ...
|
Daniel Dhumeaux
|
S30-S31
|
|
|
|
Non-invasive systems for staging compensated cirrhosis
24 February 2010
Progressive fibrosis and cirrhotic transformation of liver tissue are common pathological outcomes of most chronic liver diseases (CLDs). Although the histopathological analysis of liver tissue still ...
|
Massimo Pinzani
|
S32-S34
|
|
|
|
Cellular and molecular basis of fibrogenesis in NASH
08 February 2010
Fibrosis due to nonalcoholic steatohepatitis (NASH) develops primarily in the pericentral areas, where thin bundles of fibrotic tissue surround groups of hepatocytes and thicken the space of Disse. Th...
|
Fabio Marra,
Cristiana Bertolani,
Sara Aleffi,
Angela Provenzano,
Francesco Vizzutti
et al.
|
S35-S37
|
|
